Remove Pharma Companies Remove Pharmaceuticals Remove Trials
article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. However, recent breakthroughs in AI, such as predictive modelling, clinical trial optimisation, and personalised medicine, have demonstrated its potential.

article thumbnail

Why Do Pharma Companies Outsource to CROs?

Vial

Clinical trials play a crucial role in advancing medical breakthroughs, but effective management is essential to unlock their full potential. Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. over the forecast period (2022-2030).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

#Unshackled: The evolving definition of asset-centricity

DrugBaron

Over the next few years, the practice of asset-centric investing was honed through various iterations all designed to counter the inherent progression bias that damages returns in pharmaceutical R&D. Doing that allowed the creation of new tools that are appropriate to deploy much later in the pharmaceutical R&D process.

article thumbnail

Drug Repurposing: A New Life for Old Drugs

DrugBank

Currently, about one-third of recent drug approvals and 25% of the pharmaceutical industry's annual revenue is coming from repurposed drugs.This trend is being championed industry-wide, by public organizations and nonprofits, with numerous small companies diving in and academic publications on the subject showing great popularity.  

Drugs 71
article thumbnail

Survey Sheds Light on Current Trends & Opportunities in Site and Patient Recruitment

PPD

Site and patient recruitment vendors are vital in supporting clinical trial operations across all phases and therapeutic areas. Their services help engage a suitable participant pool, facilitate clinical trial participation, ensure that selected sites have the resources to support clinical trial activities and more.

article thumbnail

FDA Poised to Make Impact on Underrepresented Populations in Clinical Studies

H1 Blog

Increasing diversity in clinical trials not only makes the findings more relevant to various patient groups, but also enhances knowledge about the disease or medical product being studied. Hence, pharmaceutical companies need to start making preparations to ensure compliance with the new requirements.

FDA 59
article thumbnail

Best CDMO Practices for Startups: Navigating the Complex World of Contract Development and Manufacturing

Drug Patent Watch

The pharmaceutical landscape is evolving rapidly, with small and medium-sized biotech companies increasingly taking center stage in innovation. In 2017, small and medium-sized biotech companies accounted for 51% of FDA market approvals, while large pharma companies were the originators in only 28% of approvals[4].